Evaluating the Efficacy of Novel Drug Combinations Against MDR Gram-Negative Bacteria: A Comparative Study

Background: The emergence of multidrug-resistant bacterial infections has challenged the effectiveness of conventional antibiotics. Evaluating new combination therapies can help identify more effective treatment options. Aim: This study investigates the sensitivity of bacterial isolates to three antibiotic combinations—Cefepime Enmetazobactam, Ceftazidime Avibactam, and Ceftriaxone+Sulbactam+Disodium Edetate—to determine their potential role in managing multidrug-resistant infections. Methods: A total of 100 bacterial isolates were collected from urine, sputum, blood, pus, and tissue samples obtained in ICU and non-ICU settings. Antibiotic sensitivity was assessed using standard disc diffusion methods, with sensitivity rates determined for each bacterial species. Results: Ceftriaxone+Sulbactam+Disodium Edetate showed the highest sensitivity rates across all species tested, including 71.5% for Klebsiella species, 78% for Escherichia coli, 75% for Pseudomonas species, and 80% for Acinetobacter species. Cefepime Enmetazobactam and Ceftazidime Avibactam demonstrated lower sensitivities, particularly against Acinetobacter species. The findings suggest that Ceftriaxone+Sulbactam+Disodium Edetate is the most effective combination among the three tested. Conclusion: Ceftriaxone+Sulbactam+Disodium Edetate exhibits superior efficacy against a range of bacterial pathogens, making it a promising option for treating resistant infections. The other two combinations, while moderately effective, may require more targeted use. Recommendations: Further studies with larger sample sizes and diverse clinical settings are recommended to confirm these findings and develop more refined antibiotic guidelines to address multidrug resistance. Keywords: Antibiotic sensitivity, multidrug-resistant bacteria, cefepimeenmetazobactam, ceftazidime avibactam, ceftriaxone+sulbactam+disodiumedetate